The anti-resorptive medication denosumab (Prolia), although not a bisphosphonate, is included in this category because it also targets osteoclast activity through a different mechanism
Gill says if NAION is confirmed, consult with your full medical team, including your ophthalmologist, neurologist, primary care physician and endocrinologist, to make a well-informed decision on whether to continue or stop the GLP-1 medication
Average weight loss among patients was 16.2% at 12 months in the program, 17.3% at 18 months and 17.9% at 24 months, according to the report
If side effects show up, youre not CACI-eligible
Given the high rate of obesity in the teenage population, it will be valuable to track how recent approvals and label expansions impact this group